Abstract Details

Title Test-Retest Reliability of Resting State Functional Connectivity MRI in Mild Cognitive Impairment

Topic Aging and Dementia

Presentation(s) P06 - (-)

Poster/Presentation
Number 024

Objective

Background BACKGROUND: There is a growing consensus that fcMRI may be useful as a biomarker for early detection of brain dysfunction related to neurodegenerative pathology. In particular, fcMRI has shown promise in detecting early disruption of large-scale intrinsic networks, such as the default mode network (DMN), in preclinical and prodromal Alzheimer's disease. To date, there has been limited data available on fcMRI reliability in clinically impaired older subjects.

Design/Methods DESIGN/METHODS: Longitudinal resting state fcMRI data was collected on a group of 40 elderly subjects: 20 CN (age= 75.2±6.3; MMSE=28.9±1.4) and 20 amnestic MCI (age=72.7±9.4; MMSE=26.6±2). The follow-up scan interval was CN=161±18.2 days, and MCI=81.9±9 days. Test-retest reliability of DMN coherence was evaluated with established seed-based methods and a new technique we have developed in-house called Template Based Rotation (TBR).

Results RESULTS: Overall, the results from seed based analyses confirm previous reliability findings of fcMRI reliability of the DMN in healthy young indviduals (ICC approximately=0.55) with CN ICC=0.52 and MCI ICC=0.45, which was not significantly different between groups (determined by comparison of Pearson's r). The TBR method resulted in an improved CN ICC=0.71; r[sup2] change = +23% (p=0.03) and MCI ICC=0.63; r[sup2] change +19% (p=0.05).

Conclusions CONCLUSIONS: FcMRI test-retest reliability of DMN network measures in older CN and MCI subjects are comparable to what has been reported with seed-based methods in healthy young individuals. Our findings indicate that utilizing fcMRI in clinical trials for preclinical and prodromal AD is feasible, and that novel analytic methods can further improve reproducibility estimates. Studies are ongoing to identify and reduce additional sources of variability in order to maximize ability to detect subtle longitudinal changes with clinical progression and response to therapeutic intervention.

Authors/Disclosures
Aaron Schultz PRESENTER	No disclosure on file
Gad Marshall, MD (Brigham and Women's Hospital)	Dr. Marshall has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharma USA Inc. Dr. Marshall has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Beth Israel Deaconness Medical Center. Dr. Marshall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Harvard Health Publications.
Jasmeer Chhatwal, MD, PhD (Massachusetts General Hospital)	Dr. Chhatwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ExpertConnect. Dr. Chhatwal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Humana Healthcare.
Dorene M. Rentz, PsyD (Brigham and Women's Hospital)	Dr. Rentz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Digital Cognition Technologies. Dr. Rentz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurotrack.
Keith A. Johnson, MD (MGH)	Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prothena. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NervGen. An immediate family member of Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oligomerix. Dr. Johnson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AC Immune. The institution of Dr. Johnson has received research support from National Institute on Aging. The institution of an immediate family member of Dr. Johnson has received research support from Alzheimer's Association. The institution of an immediate family member of Dr. Johnson has received research support from Eli Lilly and Co. The institution of Dr. Johnson has received research support from Eisai. The institution of an immediate family member of Dr. Johnson has received research support from Eisai.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Donald McLaren	No disclosure on file
	No disclosure on file
Marco Capobianco, MD	No disclosure on file
Reisa A. Sperling, MD (Brigham and Women'S Hospital)	Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acumen. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nervgen. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oligomerix. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prothena. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vaxxinity. An immediate family member of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. An immediate family member of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. The institution of Dr. Sperling has received research support from Eli Lilly. The institution of Dr. Sperling has received research support from Eisai. The institution of Dr. Sperling has received research support from NIH.

��ɫ��

��ɫ��